Systemic inhibition of the angiotensin-converting enzyme limits lipopolysaccharide-induced lung neutrophil recruitment through both bradykinin and angiotensin II-regulated pathways

Journal of Immunology

Volumn 177, Issue 10, 2006, Pages 7233-7241

  Arndt, Patrick G ^a   Young, Scott K ^b   Poch, Katie R ^b   Nick, Jerry A ^a,b   Falk, Sandor ^c   Schrier, Robert W ^c   Worthen, G Scott ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 1A RECEPTOR; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; BRADYKININ; BRADYKININ RECEPTOR; BRADYKININ RECEPTOR AGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDRALAZINE; LIPOPOLYSACCHARIDE; LOSARTAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; MOUSE; MOUSE STRAIN; NEUTROPHIL; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION;

EID: 33750802670     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.10.7233     Document Type: Article

References (65)

1. Pfeffer, M. A., E. Braunwald, L. A. Moye, L. Basta, E. J. Brown, Jr., T. E. Cuddy, B. R. Davis, E. M. Geltman, S. Goldman, G. C. Flaker, et al. 1992. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. 327: 669-677.
2. Yusuf, S., C. J. Pepine, C. Garces, H. Pouleur, D. Salem, J. Kostis, C. Benedict, M. Rousseau, M. Bourassa, and B. Pitt. 1992. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 340: 1173-1178.
3. Schunkert, H., H. W. Hense, S. R. Holmer, M. Slender, S. Perz, U. Keil, B. H. Lorell, and G. A. Riegger. 1994. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N. Engl. J. Med. 330: 1634-1638.
4. Cambien, F., O. Poirier, L. Lecerf, A. Evans, J. P. Cambou, D. Arveiler, G. Luc, J. M. Bard, L. Bara, S. Ricard, et al. 1992. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359: 641-644.
5. Dickstein, K., and J. Kjekshus. 1999. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am. J. Cardiol. 83: 477-481.
6. Mollet, J. E., U. Dahlstrom, O. Gotzsche, A. Lahiri, K. Skagen, G. S. Andersen, and K. Egstrup. 2004. Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: results of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiographic substudy. Am. Heart J. 147: 494-501.
7. Specks, U., W. J. Martin II, and M. S. Rohrbach. 1990. Bronchoalveolar lavage fluid angiotensin-converting enzyme in interstitial lung diseases. Am. Rev. Respir. Dis. 141: 117-123.
8. Idell, S., F. Kueppers, M. Lippmann, H. Rosen, M. Niederman, and A. Fein. 1987. Angiotensin converting enzyme in bronchoalveolar lavage in ARDS. Chest 91: 525-526.
9. Marshall, R. P., S. Webb, G. J. Bellingan, H. E. Montgomery, B. Chaudhari, R. J. McAnulty, S. E. Humphries, M. R. Hill, and G. J. Laurent. 2002. Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 166: 646-650.
10. Sekizawa, K., T. Matsui, T. Nakagawa, K. Nakayama, and H. Sasaki. 1998. ACE inhibitors and pneumonia. Lancet 352: 1069.
11. Okaishi, K., S. Morimoto, K. Fukuo, T. Niinobu, S. Hata, T. Onishi, and T. Ogihara. 1999. Reduction of risk of pneumonia associated with use of angiotensin I converting enzyme inhibitors in elderly inpatients. Am. J. Hypertens. 12: 778-783.
12. Ohkubo, T., N. Chapman, B. Neal, M. Woodward, T. Omae, and J. Chalmers. 2004. Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. Am. J. Respir. Crit. Care Med. 169: 1041-1045.
13. Araki, M., T. Kanda, S. Imai, T. Suzuki, K. Murata, and I. Kobayashi. 1995. Comparative effects of losartan, captopril, and enalapril on murine acute myocarditis due to encephalomyocarditis virus. J. Cardiovasc. Pharmacol. 26: 61-65.
14. Rezkalla, S., R. A. Kloner, G. Khatib, and R. Khatib. 1990. Beneficial effects of captopril in acute coxsackievirus B3 murine myocarditis. Circulation 81: 1039-1046.
15. Godsel, L. M., J. S. Leon, K. Wang, J. L. Fornek, A. Molteni, and D. M. Engman. 2003. Captopril prevents experimental autoimmune myocarditis. J. Immunol. 171: 346-352.
16. Kupatt, C., H. Habazettl, S. Zahler, C. Weber, B. F. Becker, K. Messmer, and E. Gerlach. 1997. ACE-inhibition prevents postischemic coronary leukocyte adhesion and leukocyte-dependent reperfusion injury. Cardiovasc. Res. 36: 386-395.
17. Riaz, A. A., Y. Wang, R. Schramm, T. Sato, M. D. Menger, B. Jeppsson, and H. Thorlacius. 2004. Role of angiotensin II in ischemia/reperfusion-induced leukocyte-endothelium interactions in the colon. FASEB J. 18: 881-883.
18. Ito, H., K. Takemori, and T. Suzuki. 2001. Role of angiotensin II type 1 receptor in the leucocytes and endothelial cells of brain microvessels in the pathogenesis of hypertensive cerebral injury. J. Hypertens. 19: 591-597.
19. Bregonzio, C., I. Armando, H. Ando, M. Jezova, G. Baiardi, and J. M. Saavedra. 2003. Anti-inflammatory effects of angiotensin II AT1 receptor antagonism prevent stress-induced gastric injury. Am. J. Physiol. 285: G414-G423.
20. Li, X., H. Rayford, and B. D. Uhal. 2003. Essential roles for angiotensin receptor AT1a in bleomycin-induced apoptosis and lung fibrosis in mice. Am. J. Pathol. 163: 2523-2530.
21. Raiden, S., Y. Pereyra, V. Nahmod, C. Alvarez, L. Castello, M. Giordano, and J. Geffner. 2000. Losartan, a selective inhibitor of subtype AT1 receptors for angiotensin II, inhibits neutrophil recruitment in the lung triggered by fMLP. J. Leukocyte Biol. 68: 700-706.
22. Raiden, S., K. Nahmod, V. Nahmod, G. Semeniuk, Y. Pereira, C. Alvarez, M. Giordano, and J. R. Geffner. 2002. Nonpeptide antagonists of AT1 receptor for angiotensin II delay the onset of acute respiratory distress syndrome. J. Pharmacol. Exp. Ther. 303: 45-51.
23. Rinaldo, J. E., and J. H. Dauber. 1985. Modulation of endotoxin-induced neutrophil alveolitis by captopril and by hyperoxia. J. Leukocyte Biol. 37: 87-99.
24. Cookson, W. O., M. S. Wiseman, and D. J. Shale. 1985. Angiotensin converting enzyme and endotoxin induced lung damage in the mouse. Thorax 40: 774-777.
25. Abraham, W. M., R. M. Burch, S. G. Farmer, M. W. Sielczak, A. Ahmed, and A. Cortes. 1991. A bradykinin antagonist modifies allergen-induced mediator release and late bronchial responses in sheep. Am. Rev. Respir. Dis. 143: 787-796.
26. Eric, J., B. H. Gabra, and P. Sirois. 2003. Implication of the bradykinin receptors in antigen-induced pulmonary inflammation in mice. Br. J. Pharmacol. 138: 1589-1597.
27. Gama Landgraf, R., P. Sirois, and S. Jancar. 2003. Differential modulation of murine lung inflammation by bradykinin B1 and B2 selective receptor antagonists. Eur. J. Pharmacol. 460: 75-83.
28. Bandeira-Melo, C., A. S. Calheiros, P. M. Silva, R. S. Cordeiro, M. M. Teixeira, and M. A. Martins. 1999. Suppressive effect of distinct bradykinin B2 receptor antagonist on allergen-evoked exudation and leukocyte infiltration in sensitized rats. Br. J. Pharmacol. 127: 315-320.
29. Gama Landgraf, R., S. Jancar, A. A. Steil, and P. Sirois. 2004. Modulation of allergic and immune complex-induced lung inflammation by bradykinin receptor antagonists. Inflamm. Res. 53: 78-83.
30. Perron, M. S., F. Gobeil, Jr., S. Pelletier, D. Regoli, and P. Sirois. 1999. Involvement of bradykinin B1 and B2 receptors in pulmonary leukocyte accumulation induced by Sephadex beads in guinea pigs. Eur. J. Pharmacol. 376: 83-89.
31. Arndt, P. G., S. K. Young, and G. S. Worthen. 2005. Regulation of lipopolysaccharide-induced lung inflammation by plasminogen activator inhibitor-1 through a JNK-mediated pathway. J. Immunol. 175: 4049-4059.
32. Wagner, A., H. Herkner, W. Schreiber, A. Bur, C. Woisetschlager, G. Stix, A. N. Laggner, and M. M. Hirschl. 2002. Ramipril prior to thrombolysis attenuates the early increase of PAI-1 in patients with acute myocardial infarction. Thromb. Haemost. 88: 180-185.
33. Hirschl, M. M., A. Wagner, M. Gwechenberger, H. Herkner, M. Mullner, C. Woisetschlager, and A. N. Laggner. 1998. Attenuation of thrombolysis-induced increase of plasminogen activator inhibitor-1 by intravenous enalaprilat. Thromb. Haemost. 79: 140-143.
34. Brown, N. J., M. Agirbasli, and D. E. Vaughan. 1999. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 34: 285-290.
35. Nagata, K., T. Ishibashi, T. Sakamoto, K. Nakazato, Y. Seino, K. Yokoyama, H. Ohkawara, T. Teramoto, and Y. Maruyama. 2001. Effects of blockade of the renin-angiotensin system on tissue factor and plasminogen activator inhibitor-1 synthesis in human cultured monocytes. J. Hypertens. 19: 775-783.
36. Fogari, R., A. Mugellini, A. Zoppi, L. Corradi, P. Preti, P. Lazzari, and G. Derosa. 2002. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am. J. Hypertens. 15: 316-320.
37. Brown, N. J., M. A. Agirbasli, G. H. Williams, W. R. Litchfield, and D. E. Vaughan. 1998. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 32: 965-971.
38. Brown, N. J., S. Kumar, C. A. Painter, and D. E. Vaughan. 2002. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time. Hypertension 40: 859-865.
39. Pahor, M., L. V. Franse, S. R. Deitcher, W. C. Cushman, K. C. Johnson, R. I. Shorr, K. Kottke-Marchant, R. P. Tracy, G. W. Somes, and W. B. Applegate. 2002. Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation 105: 457-461.
40. Vaughan, D. E., S. A. Lazos, and K. Tong. 1995. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis. J. Clin. Invest. 95: 995-1001.
41. Nishimura, H., H. Tsuji, H. Masuda, T. Kasahara, M. Yoshizumi, T. Sugano, S. Kimura, H. Kawano, Y. Kunieda, S. Yano, et al. 1999. The effects of angiotensin metabolites on the regulation of coagulation and fibrinolysis in cultured rat aortic endothelial cells. Thromb. Haemost. 82: 1516-1521.
42. van Leeuwen, R. T., A. Kol, F. Andreotti, C. Kluft, A. Maseri, and G. Sperti. 1994. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 90: 362-368.
43. Mehta, J. L., D. Y. Li, H. Yang, and M. K. Raizada. 2002. Angiotensin II and IV stimulate expression and release of plasminogen activator inhibitor-1 in cultured human coronary artery endothelial cells. J. Cardiovasc. Pharmacol. 39: 789-794.
44. Erdem, Y., C. Usalan, I. C. Haznedaroglu, B. Altun, M. Arid, U. Yasavul, C. Turgan, and S. Caglar. 1999. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am. J. Hypertens. 12: 1071-1076.
45. Feener, E. P., J. M. Northrup, L. P. Aiello, and G. L. King. 1995. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J. Clin. Invest. 95: 1353-1362.
46. Ridker, P. M., C. L. Gaboury, P. R. Conlin, E. W. Seely, G. H. Williams, and D. E. Vaughan. 1993. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 87: 1969-1973.
47. Nakamura, S., I. Nakamura, L. Ma, D. E. Vaughan, and A. B. Fogo. 2000. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int. 58: 251-259.
48. Arndt, P. G., S. K. Young, J. G. Lieber, M. B. Fessler, J. A. Nick, and G. S. Worthen. 2005. Inhibition of c-Jun N-terminal kinase limits lipopolysaccharide-induced pulmonary neutrophil influx. Am. J. Respir. Crit. Care Med. 171: 978-986.
49. Fessler, M. B., S. K. Young, S. Jeyaseelan, J. G. Lieber, P. G. Aradt, J. A. Nick, and G. S. Worthen. 2005. A role for hydroxy-methylglutaryl coenzyme a reductase in pulmonary inflammation and host defense. Am. J. Respir. Crit. Care Med. 171: 606-615.
50. Nick, J. A., S. K. Young, P. G. Arndt, J. G. Lieber, B. T. Suratt, K. R. Poch, N. J. Avdi, K. C. Malcolm, C. Taube, P. M. Henson, and G. S. Worthen. 2002. Selective suppression of neutrophil accumulation in ongoing pulmonary inflammation by systemic inhibition of p38 mitogen-activated protein kinase. J. Immunol. 169: 5260-5269.
51. Morimoto, S., K. Okaishi, M. Onishi, T. Katsuya, J. Yang, M. Okuro, S. Sakurai, T. Onishi, and T. Ogihara. 2002. Deletion allele of the angiotensin-converting enzyme gene as a risk factor for pneumonia in elderly patients. Am. J. Med. 112: 89-94.
52. Souza, D. G., V. Pinho, J. L. Pesquero, E. S. Lomez, S. Poole, L. Juliano, A. Correa, Jr., M. S. de A. Castro, and M. M. Teixeira. 2003. Role of the bradykinin B2 receptor for the local and systemic inflammatory response that follows severe reperfusion injury. Br. J. Pharmacol. 139: 129-139.
53. Ridings, P. C., C. R. Blocher, B. J. Fisher, A. A. Fowler III, and H. J. Sugerman. 1995. Beneficial effects of a bradykinin antagonist in a model of gram-negative sepsis. J. Trauma 39: 81-88.
54. Ahluwalia, A., and M. Perretti. 1996. Involvement of bradykinin B1 receptors in the polymorphonuclear leukocyte accumulation induced by IL-1β in vivo in the mouse. J. Immunol. 156: 269-274.
55. Farber, H. W., D. M. Center, S. Rounds, and S. M. Danilov. 1990. Components of the angiotensin system cause release of a neutrophil chemoattractant from cultured bovine and human endothelial cells. Eur. Heart J. (11 Suppl. B): 100-107.
56. Koyama, S., E. Sato, H. Nomura, K. Kubo, M. Miura, T. Yamashita, S. Nagai, and T. Izumi. 1998. Bradykinin stimulates type II alveolar cells to release neutrophil and monocyte chemotactic activity and inflammatory cytokines. Am. J. Pathol. 153: 1885-1893.
57. Pang, L., and A. J. Knox. 1998. Bradykinin stimulates IL-8 production in cultured human airway smooth muscle cells: role of cyclooxygenase products. J. Immunol 161: 2509-2515.
58. Hayashi, R., N. Yamashita, S. Matsui, M. Maruyama, E. Sugiyama, S. Sugiyama, and M. Kobayashi. 1998. Bradykinin stimulates interleukin-8 production by human lung fibroblasts. Immunology 95: 507-511.
59. Sato, E., S. Koyama, H. Nomura, K. Kubo, and M. Sekiguchi. 1996. Bradykinin stimulates alveolar macrophages to release neutrophil, monocyte, and eosinophil chemotactic activity. J. Immunol. 157: 3122-3129.
60. Paegelow, I., S. Trzeczak, S. Bockmann, and G. Vietinghoff. 2002. Migratory responses of polymorphonuclear leukocytes to kinin peptides. Pharmacology 66: 153-161.
61. Speyer, C. L., T. A. Neff, R. L. Warner, R. F. Guo, J. V. Sarma, N. C. Riedemann, M. E. Murphy, H. S. Murphy, and P. A. Ward. 2003. Regulatory effects of iNOS on acute lung inflammatory responses in mice. Am. J. Pathol. 163: 2319-2328.
62. Mickey, M. J., K. A. Sharkey, E. G. Sihota, P. H. Reinhardt, J. D. Macmicking, C. Nathan, and P. Kubes. 1997. Inducible nitric oxide synthase-deficient mice have enhanced leukocyte-endothelium interactions in endotoxemia. FASEB J. 11: 955-964.
63. Roman, A., R. Legallo, and E. D. McGahren. 2004. Blocking of endogenous nitric oxide increases white blood cell accumulation in rat lung. J. Pediatr. Surg. 39: 48-52.
64. Ignjatovic, T., F. Tan, V. Brovkovych, R. A. Skidgel, and E. G. Erdos. 2002. Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of bradykinin B1 receptor. J. Biol. Chem. 277: 16847-16852.
65. Vaughan, D. E., J. L. Rouleau, P. M. Ridker, J. M. Arnold, F. J. Menapace, and M. A. Pfeffer. 1997. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation 96: 442-447.